• Researcher Profile

    Jennifer R. Bellon, MD

     
    Jennifer R. Bellon, MD

    Top Doctor

     
    Director, Breast Radiation Oncology
    Institute Physician


    Associate Professor of Radiation Oncology, Harvard Medical School

    Centers/Programs

    Breast Oncology
    Thoracic Oncology
    Radiation Oncology

    Office phone: 617-632-3591
    Fax: 617-632-4247
    Email: jbellon@lroc.harvard.edu

    Preferred contact method: appointment phone

    View Physician Profile
     
     

    Research Department

    Radiation Oncology

    Interests

    Breast cancer, Thoracic malignancies

    Area of Research

    Optimal Therapy for Breast Cancer

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Dana L2
    Boston, MA 02215

    Research

    Optimal Therapy for Breast Cancer

    Our research centers on the treatment of breast cancer, with a focus on the optimal integration of systemic therapy and surgery with radiation. In one randomized study, we compared the sequencing of radiation therapy and chemotherapy in women with early-stage disease following breast conservation. In another study, we examined the concurrent use of chemotherapy and radiation in (1) patients with advanced breast cancer to evaluate the toxicity of concurrent radiation and the taxanes and (2) patients with early-stage disease to examine the efficacy of concurrent radiation with cyclophosphamide, methotrexate, and 5 fluorouracil (CMF) chemotherapy. Because of the proven efficacy of trastuzumab in the adjuvant treatment of breast cancer, we plan to study the potential impact of radiation therapy on the long-term cardiac toxicity of trastuzumab.

    Dana-Farber/Brigham and Women's Hospital is also actively investigating the use of preoperative systemic therapy in operable breast cancer. We are interested in patterns of local or regional recurrences following preoperative chemotherapy. Recently, we received funding to study patterns of recurrence in a uniform group of women with HER2-positive tumors treated with preoperative Herceptin-based therapy.

    In other research, our group has focused on minimizing radiation therapy in women with low-risk disease. In collaboration with Phillip Devlin, we launched a pilot study of MammoSite partial breast irradiation. This study will limit the radiation exposure to normal tissues in carefully selected patients and improve access to breast conservation. Currently, we are also studying the feasibility and toxicity of treatment, although future studies of partial-breast irradiation will focus on treatment efficacy. Ultimately, randomized trials comparing partial breast irradiation with conventional whole breast radiation will be necessary to determine the utility of this approach.

    Select Publications

    • Bellon JR, Harris JR. Chemotherapy and radiation therapy for breast cancer: what is the optimal sequence? J Clin Oncol 2005;23:5-7.
    • Bellon JR, Livingston RB, Eubank WB, Gralow JR, Ellis GK, Dunnwald LK, Mankoff DA. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer. Am J Clin Oncol 2004;27:407-10.
    • Bellon JR, Come SE, Gelman RS, Henderson C, Shulman LN, Silver BJ, Harris JR, Recht A. The sequencing of chemotherapy and radiation therapy in early stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 2005;23:1934-40.
    • Bellon JR, Shulman LN. Breast-conserving surgery vs mastectomy: how much data do we need to gain widespread acceptance and utilization? Am J Clin Oncol 2003;2:42-4.
    • Bellon JR, Shulman LN, Come SE, Li X, Gelman RS, Silver BJ, Harris JR, Recht A. A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma. Cancer 2004;100:1358-64.
View Researcher Directory
View Nurse Directory

Find a Clinical Trial

Support Cancer
Research

Give Now